• BioRay Pharmaceutical named as 2024 Material Transfer Agreement counterparty
• BioRay's results using Sofra drugs confirm targeted anti-inflammatory activity
• Results represent external validation of robustness of Sofra data
• Demonstrates broad potential of Sofra technology platform

Noxopharm Limited (ASX:NOX) is pleased to announce positive data generated by an overseas company, BioRay Pharmaceutical, that has tested novel assets from the Sofra platform. In 2024, Noxopharm signed a Material Transfer Agreement (MTA) with BioRay, a pioneer in China's biopharmaceutical industry focusing on immune-mediated diseases. BioRay decided to investigate Noxopharm's oligonucleotides as part of its research into autoimmune diseases, specifically looking at how the oligos could be used as targeted drugs in the context of antibody-drug conjugates (ADCs). The data showed that conjugation to a specific Noxopharm oligo could be achieved, and the conjugated drug significantly improved the performance of one of BioRay's own antibodies designed to target autoimmune disease, further reducing inflammation as represented by a key biological marker. BioRay will continue its work examining Noxopharm's assets over the coming months, conducting further studies together with its own drugs. Noxopharm CEO Dr Gisela Mautner said the results not only confirm the cutting-edge value of the Sofra platform but also highlight the tremendous potential of their joint development efforts. The MTA with BioRay is just one of several with companies around the world, and Noxopharm aims to continue demonstrating the versatility and promise of the Sofra technology platform.